Skip to content

Hyperalgesia of Remifentanil in postoperative patients: A study of MTD10 using the continual reassessment method

Hyperalgesia of Remifentanil in postoperative patients: A study of MTD10 using the continual reassessment method

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TNC-11001520
Enrollment
Unknown
Registered
2011-01-28
Start date
2009-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain and analgesia

Interventions

10:eight dose levels of remifentanil were chosen before the study was started, ranging from 0.05 ug/kg.min to 0.4ug/kg.min according to clinical trials and relevant literatures reported previously. Th
10:0. 05ug/kg.min (10%), 0.10 ug/kg.min (15%), 0.15ug/kg.min (30%), 0.20ug/kg.min (40%), 0.25 ug/kg.min (55%), 0.30 ug/kg.min (70%), 0.35ug/kg.min (90%) and 0.4 ug/kg.min (99%).

Sponsors

Department of Anesthesiology, The First Hospital, China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All patients aged between 20 to 65yr with an American Society of Anesthesiologists physical status (ASA) I-II undergoing elective breast cancer surgery.

Exclusion criteria

Exclusion criteria: (1) immediate extubation was not planned after surgery; (2) they regularly took analgesics or had a history of drug or alcohol abuse; (3) they had used any drug which may interfere the results within 24h of surgery or poorly controller hypertension; (4) they had a history of cardiovascular and cerebrovascular diseases, or psychiatric disorder, or obesity (BMI>30). Pregnant patients were also excluded from the study.

Design outcomes

Primary

MeasureTime frame
pain detectin threshold;pain detectin threshold;

Secondary

MeasureTime frame
posterior response probability;

Countries

China

Contacts

Public ContactHong Ma
mahong5466@yahoo.com+86 13840366406

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026